I n patients presenting with ventricular arrhythmia, accurate determination of the etiology and risk stratification remains challenging. These patients may be at risk of further ventricular arrhythmic events, and some have an increased risk of sudden cardiac death (SCD). Although device therapy has a major protective benefit, patient selection remains difficult.
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Current guidelines recommend device therapy in preference to antiarrhythmic medication in patients who are survivors of cardiac arrest or sustained ventricular tachycardia (VT) (secondary prevention), or in those with significantly reduced left ventricular (LV) ejection fraction (EF) (primary prevention) (1). The majority of randomized controlled studies that explored either the secondary (2-4) or primary (5) prevention benefit of automated implantable cardioverter-defibrillator (AICD) either enrolled only patients with reduced LVEF or showed a predominant benefit in those with reduced EF (6) . Consequently, the device therapy guidelines target predominantly those with reduced EF. However, subsequent post hoc data analysis from the AVID (Antiarrhythmics Versus Implantable Defibrillators) randomized controlled trial (4) showed that patients with a clearly defined lower risk profile are not likely to benefit from secondary prevention AICD (7) . Coupled with reports from the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II) cohort that a significant proportion of patients implanted for primary prevention never use their device (5), the fact that defibrillator therapy remains very expensive, has certain restrictive lifestyle implications, and carries risks of complications, it would be beneficial if refinements of the current criteria could be added, on the basis of stronger indices of prediction for those patients who are at risk of further life-threatening ventricular arrhythmias.
A well-established mechanism for arrhythmia is the presence of myocardial fibrosis that predisposes to re-entrant circuits (8, 9) . Late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) is able to detect in vivo replacement fibrosis (10, 11) . CMR has emerged as an important predictor of cardiovascular mortality and morbidity in patients with both ischemic (12) (13) (14) and nonischemic cardiomyopathy (14 -21) . Several studies showed that the presence, amount of scar, and scar heterogeneity all appear to be important for both inducible and spontaneous ventricular tachycardia (VT) (22) (23) (24) (25) (26) .
However, if myocardial fibrosis is to be a strong predictor of malignant ventricular arrhythmia and not a simple bystander at the end stage of disease processes, its predictive value should extend to all patients with myocardial fibrosis, independent of their LVEF, whereas the absence of fibrosis should indicate a population with a better outcome.
We sought to test this hypothesis by analyzing the prognostic value of myocardial fibrosis in a consecutive cohort of all-comers with documented ventricular arrhythmias, with a known or suspected structural cause for arrhythmia, who were referred for CMR.
M E T H O D S
Study patients. Consecutive patients with a recent diagnosis of nonsustained VT (NSVT) or sustained VT referred for CMR to the Royal Brompton Hospital between 1999 and 2009 were prospectively enrolled for follow-up of cardiac events. Reasons for referral were further diagnostic evaluation: assessment of cardiac structure and function, known or suspected cardiomyopathy or nonacute ischemic heart disease, assessment of anomalous coronary origin, or valvular heart disease. Cases of congenital VT (catecholaminergic, Brugada, or idiopathic QT syndromes, diagnosed on the basis of the family history, electrocardiogram [ECG] , and where available, genetic testing for known genes at the time of referral) were not included in this analysis. The study was approved by the institutional ethics committee, and the subjects gave full informed consent. Cardiac magnetic resonance. A 1.5-T Siemens scanner (Siemens, Munich, Germany) was used. After localizer scans, cine images were acquired in 3 long axes, followed by a full short-axis cine stack in all patients and a LGE study. Gadolinium DTPA (Gadovist, Bayer, Berlin, Germany) was administered as a hand-injected bolus of 0.1 mmol/kg followed by a saline flush. LGE images were acquired in each corresponding long-and short-axis cine view using a 2-dimensional segmented turbo fast low-angle shot inversion recovery sequence. The inversion time was adjusted to optimize myocardial nulling. The LGE images were repeated after swapping the phase-encoding direction, and 
all areas of observed enhancement were cross-cut to exclude artifact. Image analysis. Ventricular function and volumes were analyzed with dedicated software (CMRtools, Cardiovascular Imaging Solutions, London, United Kingdom) as previously described (27) . All volume and mass measurements were indexed to body surface area (27) . The entire short-axis LGE stack of images was analyzed quantitatively for fibrosis extent by 2 independent readers with customized software (MRI-MASS, Medis, Leiden, the Netherlands). The endocardial and epicardial borders were traced for each short-axis slice. A region of interest averaging 50 mm 2 was defined within the normal remote myocardium in an area with uniform myocardial suppression free of artifacts. A multipass region-growing algorithm was used to identify the fibrotic boundaries on the basis of the "full width half maximum" technique; fibrosis was expressed as present or absent, and its extent was quantified as a percentage of total LV mass (20) . Follow-up data. Events data were collected in all cases by communication with the patient via a mailed questionnaire and by examination of the primary care physician's records as well as examination of the referring hospital records. Mortality data were cross-checked with the Office of National Statistics. Only new events after enrolment were considered in the analysis. Patients were censored after reaching the composite endpoint, which was a combination of dysrhythmic cardiac death, cardiac arrest, new episode of sustained VT or ventricular fibrillation (VF), or appropriate AICD discharge, as defined by a change in the configuration of the stored ECG (28) . Patients who underwent electrophysiology (EP) ablation for VT were censored at the time of EP ablation, as this intervention skews the natural course of an arrhythmic history. Statistical analysis. All statistical analyses were performed in SPSS version 18 (SPSS, Armonk, New York). Results are presented as mean Ϯ SD or n (%) for continuous and categorical variables, respectively. Comparisons between groups were made with the independent Student t test of chi-square cross-tabulations for continuous and categorical data, respectively. Kaplan-Meier survival curves were used to test the significance of each independent variable as a predictor of the endpoint as a comparator between groups. All demographic, clinical, and scan variables that were significant univariate predictors (with a p value Ͻ0.05) were subsequently entered in a multivariate model. Each Cox proportional hazards model was constructed using with a forward conditional stepwise procedure. The selected multivariate model was refitted without using a stepwise procedure to avoid problems of missing data in unselected variables. The assumption of proportional hazards was checked using graphical methods (29) . The predictions from some simple models were compared using the net reclassification index (30) .
R E S U L T S
Baseline characteristics. Between 1999 and 2009, a total of 373 patients were recruited. The baseline characteristics of the cohort are summarized in Table 1 . They were followed up for a median of 2.6 years (range 11 months to 11 years, interquartile range [IQR]: 1.1 to 3.6 years). Replacement fibrosis was detected in 122 (33%) of patients on the LGE study, 55 of whom received an AICD. The group with fibrosis was older by 8 years than the nofibrosis group and similar in ethnic origin. Fibrosis was present in 38% of VT patients and 27% of NSVT patients (p ϭ 0.030). Coronary artery disease (CAD) (as diagnosed by coronary angiography), heart failure (HF), and diabetes were significantly higher in the fibrosis group (p Ͻ 0.01). Fibrosis was also more frequent in men versus women (42% vs. 17%, p Ͻ 0.001). The fibrosis group was more likely to be receiving angiotensinconverting enzyme (ACE) inhibitors or betablockers compared with the no-fibrosis group (p Ͻ 0.001 for each medication). The resting ECG was abnormal in 134 patients (T-wave inversion, ST/ T-wave changes, voltage criteria of LV hypertrophy, left or right bundle branch block, atrial fibrillation, multiple ventricular ectopic beats, firstdegree atrioventricular block). After clinical evaluation (which included access to the CMR report), 116 patients with LVEF Ͼ35% were implanted with an AICD.
CMR characteristics are presented in Table 2 . The mean LVEF of the entire study population was 60 Ϯ 13%. For the entire cohort (both NSVT and VT groups), patients with fibrosis had significantly increased LV volumes and mass (both before and after they were normalized to body surface area, sex, and decile of age, p Ͻ 0.001), reduced LVEF (p Ͻ 0.001), increased right ventricular (RV) volumes (p Ͻ 0.05), and reduced RVEF (p ϭ 0.004). Fibrosis was located subepicardially (n ϭ 2), midwall (n ϭ 69), subendocardially (n ϭ 18), transmurally (n ϭ 23), or diffusely (n ϭ 10) in the total 122 patients who demonstrated late enhancement.
Patients with each of the 2 clinical presentations were also analyzed separately (Table 2 ). In the VT group, patients with fibrosis showed significant LV and RV remodeling compared with those without fibrosis. In the NSVT group, there was significant LV remodeling in those with fibrosis, but there were no differences in the RV volume parameters between groups. When fibrosis was present, the amount of fibrosis measured in the LV was comparable between the VT and NSVT subgroups. Hard events. During follow-up, there were 6 noncardiac deaths, and 15 patients underwent EP ablation, all for VT. Fifty-three patients (35 in the VT and 18 in the NSVT group) reached the composite endpoint (15 [28%] cardiac death, 1 [1.8%] cardiac arrest, 15 [28%] AICD discharge, 22 [41%] sustained VT); and 9 patients met the primary outcome on 2 occasions (but were censored at first event for analysis). Of the 53 reaching the primary outcome, 33 (62%) were in the fibrosis group. For the entire cohort, variables that were found to be significant univariate predictors of the primary outcome were a past medical history of CAD (log-rank chi-square test ϭ 5.8, p ϭ 0.016), an increased LV end-systolic volume (log-rank chi-square test ϭ 5.2, p ϭ 0.023), and presence of LGE fibrosis (log-rank chi-square test ϭ 22, p Ͻ 0.001). Reduced LVEF was a significant predictor of events in the univariate analysis, whether it was represented with a cutoff at LVEF Ͻ55% (log-rank chi-square test ϭ 10, p ϭ 0.002), or a cutoff at LVEF Յ35% (log-rank chi-square test ϭ 6.1, p ϭ 0.014), or as 3 categories (Յ35, 36 to 54, Ն55, log-rank chi-square test ϭ 11.3, p ϭ 0.004) (Fig. 1A) . Reduced RVEF was similarly associated with the events, but added nothing extra when fitted in the same model with LVEF. The most inclusive list of variables offered to the forward stepwise selection included past medical history of myocardial infarction, of CAD and of HF, family history of SCD, LV end-systolic volume category, presence of LGE fibrosis, and a representation of LVEF. In the multivariate model, the presence of fibrosis was the only independent predictor of the primary outcome (hazard ratio [HR]: 3.3, 95% confidence interval [CI]: 1.8 to 5.8, p Ͻ 0.001). LVEF Ͻ55% had an elevated HR, but was not significant at the 5% significance level for the primary outcome after adjusting for presence of fibrosis (HR: 1.4, 95% CI: 0.7 to 2.5, p ϭ 0.31). No other representations of Values are mean Ϯ SD or n. Where a characteristic is clearly binary (medication used or not, disease present or not), only the counts for 1 of the 2 categories is presented, and the p value is presented on the same row as the name of the characteristic. The p value represents comparisons between the LGE fibrosis negative (Ϫ) and LGE fibrosis positive (ϩ) groups. ACE ϭ angiotensin-converting enzyme; LGE ϭ late gadolinium enhancement; NSVT ϭ nonsustained ventricular tachycardia; VT ϭ ventricular tachycardia.
LVEF (cutoff at Յ35% or in 3 categories: LVEF Յ35, 36% to 54%, Ն55%) were significant after adjusting for fibrosis. Given the significance of the multivariate analysis of presence/absence of fibrosis for the combined outcome, data were also represented with a cutoff at the median value of 10% fibrosis: relative to having no fibrosis, having Ͻ10% fibrosis, or Ն10% fibrosis showed a comparable hazard of the composite endpoint (HR: 3.5, 95% CI: 1.8 to 6.7; and HR: 3.7, 95% CI: 1.9 to 7.3, respectively). Figure 1B shows the survival analysis of the patients with fibrosis compared with those without fibrosis, and Figure 1C shows the increase in absolute risk of reaching the composite endpoint for all patients with presence of fibrosis. Subgroup analyses. In the sustained VT group, the univariate variables that significantly influenced survival were a past medical history of CAD (chisquare test ϭ 10.2, p ϭ 0.001) as well as presence of LV fibrosis (chi-square test ϭ 12.1, p Ͻ 0.001).
Reduced LVEF was a significant univariate predictor whether divided into 3 categories, that is, LVEF Յ35%, 36% to 54%, Ն55%, (chi-square test ϭ 13.2, p ϭ 0.001) ( Fig. 2A) or using a cutoff at LVEF Յ35% (chi-square test ϭ 12.9, p Ͻ 0.001), but not quite significant at the 5% level as a cutoff at LVEF Ͻ55%.
The most inclusive list of variables offered to the forward stepwise selection included past medical history of CAD and of HF, family history of SCD, presence of LGE fibrosis, and a representation of LVEF. Both LV fibrosis and a severely impaired systolic function (LVEF Յ35%) appeared to be significant predictors in the multivariate model (HR: 3.0, 95% CI: 1.4 to 6.2, p ϭ 0.001, and HR: 2.5, 95% CI: 1.1 to 6.2, p ϭ 0.038, respectively). There was no evidence of an interaction between fibrosis and LVEF.
With a similar cutoff at the median value of 10%, having Ͻ10% fibrosis, relative to having no fibrosis, increased the hazard of the composite endpoint (HR: 2.9, 95% CI: 1.2 to 6.9), and having Ն10% fibrosis similarly increased the risk (HR: 3.8, 95% CI: 1.7 to 8.2). Figure 2B shows the survival analysis of the VT patients with fibrosis compared with those without fibrosis. Figure 2C shows the increase in absolute risk of reaching the composite endpoint for the VT patients with presence of fibrosis.
In the NSVT group, the univariate variables that predicted the likelihood of reaching a primary outcome were the LV mass index (log-rank chisquare test ϭ 4.6, p ϭ 0.031), LVEF Ͻ55% (log-rank chi-square test ϭ 7.2, p ϭ 0.007), and the presence of LV fibrosis (log-rank chi-square test ϭ 8.8, p ϭ 0.003). (LVEF represented as 3 categories was also a significant predictor [log-rank chi-square test ϭ 13.5, p ϭ 0.001], but LVEF cutoff at 35% was not.) The most inclusive list of variables offered to the forward stepwise selection included past medical history of CAD and of HF, family history of SCD, LGE (؊) (n ‫؍‬ 251)
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LGE Figure 3A shows the estimated survival analysis of the NSVT patients with fibrosis compared with those without fibrosis. Although there was an elevated HR for the percentage of fibrosis, it was not statistically significant (HR: 1.09, 95% CI: 0.91 to 1.29, p ϭ 0.331). Relative to having no fibrosis, having Ͻ10% fibrosis significantly increased the hazard of the composite endpoint (HR: 5.9, 95% CI: 2 to 17.3), but having Ն10% fibrosis did not (HR: 2.4, 95% CI: 0.7 to 8) (Fig. 3B) . The unadjusted and adjusted hazard ratios for all variables included in the Cox multivariate models are presented in Table 3 .
A net reclassification index (30) ). Higher proportions were classified as high risk using LGE Ն10% (34% of patients with the outcome and 14% without) than LVEF Յ35% (15% and 6%, respectively). Overall, there was marginally better risk prediction of the composite endpoint on the basis of LGE than on LVEF, but this did not reach statistical significance (p ϭ 0.10). Patients with VT showed the same modest improvement in prediction with LGE than LVEF (p ϭ 0.13), and there was no difference for patients with NSVT (p ϭ 0.59).
D I S C U S S I O N
The main findings of this study are:
1. In patients presenting with ventricular arrhythmia (excluding those with arrhythmia of congenital or genetic etiology), the presence of myocardial fibrosis is an important independent predictor of the combined endpoint of cardiac death, cardiac arrest, new episode of sustained VT, VF, or appropriate AICD discharge. 2. In patients who presented with an episode of sustained VT, both the presence of fibrosis on CMR-LGE and a poor LVEF (Յ35%) were significant predictors of the combined endpoint. In this study, the assessment of fibrosis was not only an LGE (-)
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LGE % Hazard ratios for reaching the composite endpoint for all 373 study patients grouped into 3 categories: no fibrosis, Ͻ10% fibrosis, or Ն10% fibrosis.
independent predictor, but also a better predictor of the composite endpoint than LVEF. 3. In patients who presented with a previous episode of NSVT, the presence of fibrosis on CMR-LGE was the only independent predictor of the combined endpoint.
These findings suggest that assessment of myocardial fibrosis could be complementary to measurement of LVEF for risk stratification and could bring refinements to the current criteria for prescription of AICD as well as identify other highrisk groups that did not previously qualify.
A well-recognized mechanism for sudden cardiac death is the presence of fibrosis causing electrical instability in the LV myocardium through re-entrant arrhythmias (31) . In EP studies, a key aim is to identify areas of fibrosis as a focus for ablation. The negative predictive value of a normal LGE-CMR has already been suggested in smaller studies, for example, absence of fibrosis in nonischemic cardiomyopathy identified a group at much lower risk (24) . Conversely, the presence of fibrosis in hypertrophic cardiomyopathy (17, 18, 32) , ischemic cardiomyopathy (22), or other nonischemic (21) cardiomyopathy identified those at higher risk. However, most of these studies followed up patients who already qualified for an AICD by the current criteria and therefore most had severely depressed EF (Ͻ35%). Implications for secondary prevention. Our current study was novel in enrolling all comers with VT and NSVT, so that we can adequately compare the individual impacts of LGE and LV remodeling with respect to their predictive values. Indeed, the mean EF of our study population was 60 Ϯ 13%. This is markedly different from the landmark studies on the basis of which AICD is recommended for secondary prevention by the current guidelines: in the AVID trial (4), the mean EF of patients was 32%; in CASH (Cardiac Arrest Study Hamburg) (2), the mean EF was 46%; and in CIDS (Canadian Implantable Defibrillator Study) (3), the mean EF was 33%. Our findings in the VT subgroup, which identified an EF Յ35% and the presence of LV fibrosis as the only 2 important predictors of hard cardiovascular events after multivariate analysis, is in agreement with the earlier studies: a poor EF is a significant predictor of further ventricular arrhythmia. However, an important finding in this study is that the presence of LV fibrosis appears to be a stronger predictor of events, even in those with poor EF. The implication that in those with mild-to-moderate LV impairment or normal LVEF, the presence of fibrosis is in fact the LGE (-)
LGE ( only significant predictor of events, warrants further exploration. Although current guidelines for AICD implantation as secondary prevention list those with sustained VT and structural heart disease as a Class I, Level of Evidence: B indication, it is conceivable that in vivo detection of fibrosis may be able to identify those patients with structural heart disease who could derive particular benefit from AICD prescription. Our findings are in agreement with the findings of Iles et al. (24), who showed a significant difference between groups of patients with structural heart disease who had fibrosis versus those without fibrosis with respect to recurrence of ventricular arrhythmia episodes.
Of the randomized controlled studies that compared AICD implantation with antiarrhythmic medication for secondary prevention, only AVID demonstrated a statistically significant survival benefit. This implies that better discrimination of those patients who will use an AICD is desirable. If confirmed by other studies, our findings have the potential to refine the criteria for secondary prevention, as already challenged by post hoc analyses of landmark studies that identified that patients at lower risk may not benefit from AICD implantation (7) . Risk stratification inclusive of LV fibrosis may contribute as a robust biomarker for arrhythmia recurrence in these patients. Implications for primary prevention. The primary prevention of ventricular arrhythmias remains a subject of intense debate. The group we studied has an element of self-selection, as they already presented with an NSVT episode rather than being arrhythmia naive (the same applied to randomized controlled studies of primary prevention, for example, in those with nonischemic cardiomyopathy enrolled in the DEFINITE [Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation] trial [33] ). Although a depressed EF (Յ35%) is the mainstay for favoring AICD therapy in the current guidelines, almost irrespective of etiology, our results were unable to confirm this because we had very few patients in the NSVT subgroup with severely impaired EF (Յ35%): 12 of 169. This is, of course, expected, as in accordance with current guidelines, those with poor EF would have been prescribed an AICD by their attending cardiologist, and further investigation before device placement would often be deemed unnecessary. For the remaining majority of patients presenting with NSVT, our results showed that the presence of fibrosis was the only predictor of the combined outcome. This result is interesting because it opens new avenues of consideration for primary prevention in groups that are not included by guidelines and are treated by individual consideration in current medical practice. Study limitations. Inevitably, there will be some referral bias dependent on referring physician practice. It is conceivable that those at greatest risk were not referred because an AICD was considered mandatory on the basis of current guidelines. Also, risk in this work is determined on the basis of a fixed rather than a progressive review based on stratified assess- LGE (-)
LGE ( ment. Our quantitative analysis of fibrosis assumed calibration of signal intensity to a remote area of myocardium considered normal-in practice it is also conceivable that in disease states, diffuse fibrosis may be present in the remote myocardium, and if so, this would slightly alter the amount of calculated replacement fibrosis by this technique.
In this study, we evaluated the prognostic significance of LV fibrosis in patients presenting with a ventricular arrhythmia. Patients with detectable myocardial fibrosis had a significantly higher risk of reaching the combined outcome of cardiac death, cardiac arrest, new episode of sustained VT or VF, and appropriate AICD discharge. The presence of fibrosis was the most significant independent predictor in multivariate analyses and may have merit as an important biomarker for further risk stratification. These findings have the potential to bring significant refinement in prescribing AICD therapy for both primary and secondary prevention. LGE 0% 1.00 Overall Ͻ0.001 23.5
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